Gilead Sciences, Inc. $GILD Shares Sold by AEGON ASSET MANAGEMENT UK Plc

AEGON ASSET MANAGEMENT UK Plc decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 243,581 shares of the biopharmaceutical company’s stock after selling 9,648 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc’s holdings in Gilead Sciences were worth $27,030,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC grew its stake in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new position in Gilead Sciences in the third quarter valued at $26,000. Harbor Asset Planning Inc. acquired a new position in Gilead Sciences during the 2nd quarter worth $27,000. Howard Hughes Medical Institute purchased a new stake in Gilead Sciences during the 2nd quarter worth about $30,000. Finally, Putney Financial Group LLC raised its position in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 3.7%

Shares of NASDAQ:GILD opened at $135.93 on Monday. Gilead Sciences, Inc. has a 1-year low of $92.26 and a 1-year high of $136.30. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock has a market cap of $168.65 billion, a P/E ratio of 21.07, a P/E/G ratio of 0.71 and a beta of 0.33. The firm has a fifty day moving average price of $123.98 and a 200 day moving average price of $118.71.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.3%. Gilead Sciences’s payout ratio is presently 48.99%.

Insider Buying and Selling at Gilead Sciences

In other news, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director owned 1,339 shares in the company, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at approximately $1,101,620. The trade was a 35.92% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 141,757 shares of company stock valued at $17,569,112. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the subject of a number of recent research reports. UBS Group reiterated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, January 15th. Scotiabank started coverage on Gilead Sciences in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price on the stock. BMO Capital Markets restated an “outperform” rating on shares of Gilead Sciences in a research note on Tuesday, January 13th. Rothschild & Co Redburn lifted their price target on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Finally, Wells Fargo & Company upped their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $133.52.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.